Clinical Trial Update: Dose-Escalation Study to Evaluate the Safety and Immunogenicity of MTBVAC Vaccine in Comparison With BCG Vaccine. [Phase 1]

View source ↗

Summary

Phase 1 dose-escalation study comparing the safety and immunogenicity of the MTBVAC vaccine to the BCG vaccine has completed, with results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Tuberculosis

Drugs mentioned

• BCG vaccine (Bacillus Calmette-Guérin)
• MTBVAC

Snippet

Sponsor: Biofabri, S.L | Conditions: Tuberculosis, Healthy | Phase 1 | Status: COMPLETED | Results posted: 2017-03-24